Search results | viropharma


Partnering Agreements with Viropharma

The Partnering Agreements with Viropharma report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.


Dealtalk: ViroPharma Said to Hire Goldman Amid Sanofi Interest

According to dealtalk, ViroPharma began working with Goldman Sachs Group Inc. on a possible auction after fielding an unsolicited approach.

Pharma rumour mill: ViroPharma attracts takeover interest

Pharma rumour mill circulates hint that ViroPharma is attracting preliminary acquisition interest from several pharmaceutical companies.

Viropharma: Company profile

Viropharma: Company profile

Return to bigbiotech list

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Orphan Diseases: recent partnering deal trends

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

Top Life Science M&A Deals and Trends in 2013

With over 450 deals announced, 2013 was a big year for mergers and acquisitions in the life sciences

Current Agreements Deal Analysis Update : December 2013

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in November 2013

CurrentAgreements Deals Update: October 2011

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in September 2011


Sorry, your search returned no results.


Acquisition agreement for ViroPharma for $4.2 billion

Shire has agreed to pay $4.2 billion in cash for the acquisition of ViroPharma.

Acquisition agreement for DuoCort Pharma

Definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy.